Whenever new governmental policies affect investments, investors can normally adapt to the situation. Normally, these policies will steer the industry in a certain direction that can be rather predictable. It is much more difficult, though, when governmental policy goes in opposing directions. Based on current legislative proposals, it appears that the federal government wants to go in one direction while Alaskans want to go in the other.�
Let's look at what's going on with these two opposing proposals and what it could mean for investors in the energy industry.
Flaming out fossil fuels
The most recent budget proposal from the Obama administration can be viewed through several lenses, but the overlying theme is to foster greater alternative energy growth and increase governmental revenue from fossil fuels. Whether you agree with this policy or not, it's clear that energy is one of the focal points of the budget, with the Department of Energy receiving an 8% increase in spending in the face of several departments seeing budget cuts.�
Hot Casino Stocks To Buy For 2015: GenMark Diagnostics Inc.(GNMK)
GenMark Diagnostics, Inc. operates as a molecular diagnostics company primarily in the United States. It focuses on the development and commercialization of multiplexed molecular diagnostic testing systems for the detection and measurement of DNA and RNA targets used in the treatment of patients. The company?s products comprise eSensor XT-8 system, an automated molecular diagnostic system, which enable reference laboratories and hospitals to perform molecular diagnostic tests; and eSensor XT-8 Cartridge that utilizes a microfluidic system to accelerate target binding and enhance time to result. It also offers IVD tests, including eSensor cystic fibrosis genotyping test, eSensor thrombophilia risk test, and eSensor warfarin sensitivity test. The company?s other multiplexed molecular diagnostic tests pipeline under development comprise eSensor 2C19 test for the multiplexed detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; eSensor respiratory viral panel, a nucleic acid multiplex test for the simultaneous detection and identification of multiple respiratory virus nucleic acids and mutations that confer resistance of Influenza A to the anti-viral drug Oseltamivir (Tamiflu); and eSensor KRAS/BRAF test for the multiplexed detection and genotyping of 12 mutations in codons 12 and 13 of KRAS and the V600E mutation in BRAF. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Advisors' Opinion:- [By Sean Williams]
What: Shares of GenMark Diagnostics (NASDAQ: GNMK ) , a molecular diagnostics company, slumped as much as 10% after updating its full-year revenue guidance after the bell last night.
- [By Roberto Pedone]
GenMark Diagnostics (GNMK) is a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the U.S. This stock closed up 1.7% to $9.89 in Tuesday's trading session.
Tuesday's Range: $9.24-$9.95
52-Week Range: $6.38-$16.00
Thursday's Volume: 562,000
Three-Month Average Volume: 385,008From a technical perspective, GNMK bounced modestly higher here with above-average volume. This stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $8.75 on the downside and $10.71 on the upside. This bounce is starting to push GNMK within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern. That breakout will hit if GNMK manages to clear some near-term overhead resistance levels at $10.04 to $10.50 and then once it takes out more resistance at $10.71 with high volume.
Traders should now look for long-biased trades in GNMK as long as it's trending above Tuesday's low of $9.24 or around $9 and then once it sustains a move or close above those breakout levels with volume that hits near or above 385,008 shares. If that breakout triggers soon, then GNMK will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $13.50.
Top 5 Healthcare Equipment Companies To Own In Right Now: KaloBios Pharmaceuticals Inc (KBIO)
KaloBios Pharmaceuticals, Inc., is a United States-based company, which develops protein therapeutics. The Company develops and engineers antibodies and protein therapeutics. Its monoclonal antibodies (mAbs) technology that is being used for reengineering antibodies with products being developed in the areas of infectious disease, autoimmunity, and oncology. Its suite of technologies can also be used for discovery and engineering of other proteins, industrial enzymes and small molecule drugs. It conducts three clinical development programs in leukemia, infectious diseases, and autoimmune diseases. Advisors' Opinion:- [By Monica Gerson]
KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) shares fell 64.48% to $0.65 in pre-market trading after the company reported top-line data from phase 2 study of KB001-A.
Top 5 Healthcare Equipment Companies To Own In Right Now: MGP Ingredients Inc.(MGPI)
MGP Ingredients, Inc. produces ingredients and distillery products in the United States. It processes wheat flour and corn into various products through an integrated production process. The company operates in three business segments: Ingredient Solutions, Distillery Products, and Other. The Ingredient Solutions segment products consist of specialty proteins, specialty starches, vital wheat gluten, commodity wheat starch, and mill by-products. The Distillery Products segment offers food grade alcohol; fuel grade alcohol, commonly known as ethanol; and distiller?s feed and carbon dioxide, which are co-products of the company?s distillery operations. The Other segment products comprise resins, and plant-based polymers and composites. MGP Ingredients, Inc. sells its products directly or through distributors to the manufacturers and processors of finished goods. The company was founded in 1941 and is headquartered in Atchison, Kansas.
Advisors' Opinion:- [By John Udovich]
Shares of small cap stocks VASCO Data Security International, Inc (NASDAQ: VDSI), MGP Ingredients Inc (NASDAQ: MGPI) and Planar Systems, Inc (NASDAQ: PLNR) are up 277.7%, 228.5% and 222%, respectively, since the start of the year with all three stocks being in rather interesting or overlooked sectors e.g. data/cloud security, alcohol/ingredients and display/digital signage technology. Here is what you need to know or be warned about all three small cap stocks:
- [By John Udovich]
Small cap ingredients stock Balchem Corporation (NASDAQ: BCPC) jumped 22.76% yesterday on news about an acquisition, meaning its worth taking a closer look at the stock along with potential peers like small cap MGP Ingredients Inc (NASDAQ: MGPI) and the PowerShares Dynamic Food & Beverage ETF (NYSEARCA: PBJ).
Top 5 Healthcare Equipment Companies To Own In Right Now: TearLab Corporation(TEAR)
TearLab Corporation operates as an ophthalmic device company. It engages in developing and commercializing TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease. The company?s system enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, which is a single-use microfluidic microchip; TearLab pen, which is a hand-held device that interfaces with the TearLab disposable; and TearLab reader, which is a small desktop unit that allows for the docking of the TearLab disposable and the TearLab pen, as well as provides a quantitative reading for the operator. TearLab Corporation markets its system through a network of distributors in North America, Europe, and Asia. The company, formerly known as OccuLogix, Inc., was founded in 1996 and is headquart ered in San Diego, California.
Advisors' Opinion:- [By Seth Jayson]
TearLab (Nasdaq: TEAR ) reported earnings on May 13. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), TearLab beat expectations on revenues and exceeded expectations on earnings per share. - [By Roberto Pedone]
One potential earnings short-squeeze candidate is in-vitro diagnostic player TearLab (TEAR), which is set to release numbers on Tuesday after the market close. Wall Street analysts, on average, expect TearLab to report revenue of $3.51 million on a loss of 13 cents per share.
This company has managed to top Wall Street estimates two times over the last four quarters, which is a bullish earnings trend. If TearLab can delve another beat, then shares could be setting up for a large move higher.
The current short interest as a percentage of the float for TearLab is extremely high at 37.1%. That means that out of the 25.54 million shares in the tradable float, 8.59 million shares are sold short by the bears. This is a huge short interest on a stock with a very low tradable float. If the bulls get the earnings news they're looking for, then shares of TEAR could easily explode higher post-earnings as the bears jump to cover some of their bets.
From a technical perspective, TEAR is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last six months, with shares moving higher from its low of $5.26 to its recent high of $15.18 a share. During that uptrend, shares of TEAR have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of TEAR within range of triggering a major breakout trade post-earnings.
If you're bullish on TEAR, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $14.28 to its 52-week high at $15.18 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 942,598 shares. If that breakout hits, then TEAR will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside
No comments:
Post a Comment